Yes, this is an excellent practice for both convenience and accuracy
The lifetime cardiovascular, renal, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 RAs, and nonsteroidal mineralocorticoid receptor antagonists compared to standard care in T2D patients with albuminuria were recently evaluated by Neuen et al
Obesity Clinical Development Pipeline Muscle and Body Composition Other assets focused on preventing muscle loss in combination with incretin mimetics include Regenerons Phase 2 trevogrumab (myostatin) + garetosmab (ActA) combination, BioAges Phase 2 azelaprag (APJ), and Scholar Rocks Phase 2 apitegromab (myostatin)
Use of XTT-assay to assess the cytotoxicity of different surfactants and metal salts in human keratinocytes (HaCaT)
Cominacini M, Valenti MT, Braggio M, et al
are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in Qsymia